ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s stock price rose 4.6% during trading on Thursday . The stock traded as high as $8.27 and last traded at $8.21. Approximately 60,369 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 103,118 shares. The stock had previously closed at $7.85.
Wall Street Analysts Forecast Growth
ABVX has been the topic of several recent analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Citizens Jmp upgraded ABIVAX Société Anonyme to a "strong-buy" rating in a research note on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $38.67.
View Our Latest Stock Report on ABVX
ABIVAX Société Anonyme Price Performance
The stock has a fifty day moving average price of $6.82 and a two-hundred day moving average price of $8.86.
Institutional Investors Weigh In On ABIVAX Société Anonyme
A number of institutional investors have recently made changes to their positions in ABVX. GAMMA Investing LLC bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at approximately $29,000. R Squared Ltd bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at approximately $36,000. Bank of America Corp DE grew its stake in ABIVAX Société Anonyme by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after buying an additional 1,990 shares during the last quarter. Ameriprise Financial Inc. bought a new position in ABIVAX Société Anonyme during the 4th quarter worth $85,000. Finally, Guggenheim Capital LLC bought a new position in ABIVAX Société Anonyme during the 4th quarter worth $92,000. 47.91% of the stock is currently owned by institutional investors.
ABIVAX Société Anonyme Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
